Alimta

... cantonrep.com HOME CLASSIFIEDS JOBS REAL ESTATE AUTO COMMUNITY CALENDAR MAKE PAYMENT CLEAR21ºF weather sponsored by Search Local Obituaries Sports Lifestyle Financial Offbeat Ohio Opinion Entertainment News Elsewhere Rep Columnists Lottery Photo Gallery Newspaper Info Subscribe Advertise Registered Users E-mail Password Non-Registered Users Click Here Lost Password?

Comment on this story.Eli Lilly’s vital signs are good, but skeptics remainFriday, January 27, 2006 By THERESA AGOVINO AP Business Writer NEW YORK (AP) — Eli Lilly and Co.

has been largely immune from many of the woes bedeviling the pharmaceutical industry, and the company’s chief executive can tick off the reasons why.

Lilly avoided mergers, embraced the biotech revolution early, partnered with smaller companies and pours a larger than average percentage of revenues back into research, said chairman and CEO Sidney Taurel.

The result: Lilly introduced nine new drugs in the last four years, the pipeline holds additional promising drugs and no significant patent expirations are imminent.

And the company recently hasn’t had to withdraw a product or launch a major restructuring to shore up earnings like some of its brethren.

“I think history is proving us right if you look at our stock price,” said Taurel, looking confident and relaxed as he sat in the lobby of a Manhattan hotel.

Late last year, Indianapolis-based Lilly said its estimates for 2006 were above Wall Street’s...

Read more...